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E-mail address: christa.buechler@klinik.uni-regensGalectin-3 plays a role in atherosclerotic diseases, and the effect of adiponectin that protects from
atherosclerotic diseases on monocytic galectin-3 was analysed. Adiponectin reduced galectin-3
mRNA, its cellular and soluble form, and this effect was impaired in T2D cells. Cellular galectin-3
was higher in monocytes of overweight than normal-weight donors and was highest in T2D cells.
Cellular galectin-3 positively correlated with the BMI of the donors and negatively with soluble
monocyte galectin-3. Circulating levels of total adiponectin did not correlate with cellular or soluble
galectin-3 indicating that additional factors contribute to higher cellular monocytic galectin-3 in
obesity and T2D.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction of galectin-3 compared to stable lesions [8]. In the multiple lowType 2 diabetes is characterized by a chronic, low grade inﬂam-
mation, and this may contribute to macrovascular diseases, com-
mon complications of insulin resistance [1–4]. Galectin-3 is a 26-
kDa lectin known to regulate immune response and inﬂammation
[5]. Monocytes express signiﬁcant amounts of galectin-3, and
phagocytic differentiation as well as modiﬁed low-density lipopro-
teins induce galectin-3 expression [6]. On the other hand, lipopoly-
saccharide and interferon-c decrease galectin-3 in human
monocytes [7]. Galectin-3 is found in the nucleus, the cytoplasma,
on the cell surface and in the extracellular space, and localization
may deﬁne the biological role of galectin-3 [5].
Exogenously provided galectin-3 promotes respiratory burst in
monocytes, acts itself as a chemoattractant for monocytes and
macrophages, and upregulates CC chemokine expression in these
cells [5,8]. In addition, galectin-3 inﬂuences adhesion of immune
cells to extracellular matrix proteins and promotes apoptosis
[9,10]. Endogenous galectin-3, however, is an anti-apoptotic factor,
and this is partly explained by stabilization of basal and epidermal
growth factor stimulated increase in K-Ras-GTP complexes [11,12].
Galectin-3 deﬁciency in the apolipoprotein E knock-out mouse
model of atherosclerosis is associated with fewer atheromatous
plaques and a lower number of perivascular inﬂammatory inﬁl-
trates [13]. In unstable plaques macrophages produce higher levelschemical Societies. Published by E
burg.de (C. Buechler).doses of streptozotocin model of diabetes galectin-3 deﬁcient mice
are relatively resistant to hyperglycemia. Islet inﬂammation is re-
duced and this is partly explained by a lower TNF expression of
inﬁltrating macrophages [14]. Therefore, most of the data pub-
lished so far indicate that galectin-3 deﬁciency protects from
inﬂammation associated with metabolic diseases like atherosclero-
sis or type 2 diabetes. Nevertheless, in a murine asthma model
endogenous galectin-3 promoted inﬂammation whereas pharma-
cological application of this protein was protective [15,16].
Adiponectin is an adipose tissue derived protein with antidia-
betic and antiatherosclerotic functions but systemic levels are re-
duced in obesity, type 2 diabetes and cardiovascular disease
[17,18]. In animal models elevated adiponectin results in a marked
alleviation of atherosclerotic lesions [19]. Adiponectin suppresses
the proliferation of myelomonocytic progenitor cells and induces
apoptosis and this may contribute to the antiinﬂammatory effects
of this adipokine [20,21]. In macrophages adiponectin reduces the
release of inﬂammatory cytokines and chemokines, and the uptake
of modiﬁed lipoproteins [20,22–24].
Adiponectin exhibits pro- and antiinﬂammatory properties
in vitro [20,23,25], and it is suggested that adiponectin-mediated
activation of NFjB induces macrophage tolerance to subsequent
inﬂammatory stimuli thereby explaining the contradictory
in vitro ﬁndings [26]. Adiponectin circulates as trimer, hexamer
and higher-order multimer (HMW) in serum, and isoform-speciﬁc
effects on NFjB have been described [20,27,28]. Adiponectin acti-
vates the AMP-activated protein kinase (AMPK) that is also stimu-lsevier B.V. All rights reserved.
Table 2
Anthropometrical and biochemical characteristics of the male study group used to
measure galectin-3 in the supernatants.
T2D OW NW P-value
Probands (n) 23 20 20
Age (year) 60 (42–81) 56 (40–75) 62 (49–73)
BMI (kg/m2) 30.0 (23.0–
56.2)
29.8 (26.7–
36.5)
23.4 (20.0–
24.9)
<0.001b,c
WHR 1.05 (0.80–
1.11)
1.01 (0.9–
1.13)
0.97 (0.83–
1.06)
0.002b,
<0.001c
Glucose (mg/dl) 143 (88–
170)
87 (74–
110)
85 (70–
115)
<0.001a,c
HDL (mg/dl) 47 (33–60) 59 (34–78) 56 (42–80) <0.001a,c
LDL (mg/dl) 91 (67–
160)
117 (64–
212)
100 (54–
234)
0.002a
Soluble galectin-3
(ng/ml)
11.4 (5.0–
38.4)
14.7 (7.3–
40.0)
21.3 (7.5–
46.4)
0.043a,
0.003c
Medication
ACEI 3 2
Beta blockers 5 2 1
Diuretics 7 2 0
Lipid-lowering 4 3 1
Metformin 19 0 0
Insulin 3 0 0
Angiotensin converting enzyme inhibitor (ACEI), body mass index (BMI), high-
density lipoprotein (HDL), low-density lipoprotein (LDL), normal-weight controls
(NW), overweight controls (OW), type 2 diabetes (T2D), waist to hip ratio (WHR).
a Signiﬁcance of T2D versus OW.
b Signiﬁcance of OW versus NW.
c Signiﬁcance of T2D versus NW.
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carboxamide-1-4-ribofuranoside (AICAR) [29–31] and has been re-
ferred to as the ‘‘metabolic master switch” [32]. Besides its central
role in metabolism AMPK suppresses inﬂammation and modulates
cytokine signaling pathways in macrophages to promote polariza-
tion to an antiinﬂammatory phenotype [30].
Although the role of galectin-3 has been analysed in atheroscle-
rotic lesions its expression in monocytes of overweight and type 2
diabetes patients, and its regulation by metabolites which are al-
tered in insulin resistance, have not been studied so far.
Therefore, the inﬂuence of adiponectin on monocytic galectin-3
was analysed, and the abundance of endogenous and soluble galec-
tin-3 was determined in monocytes of type 2 diabetic patients and
suitable controls.
2. Materials and methods
2.1. Materials
Full-length recombinant human adiponectin expressed in a
mammalian cell line, and adiponectin ELISA were from R&D Sys-
tems (Wiesbaden-Nordenstadt, Germany). Vacutainer CPT and
galectin-3 antibody for immunoblot were from Becton Dickinson
(Franklin Lakes, NJ). GAPDH antibody was from New England Bio-
labs GmbH (Frankfurt, Germany). Galectin-3 ELISA was from Bend-
erMedSystems (Vienna, Austria). LightCycler FastStart DNA Master
SYBR Green I was purchased from Roche (Mannheim, Germany).
Metformin, AICAR, palmitic acid and oleic acid were ordered from
Sigma (Deisenhofen, Germany). Fatty acids were complexed to
fatty acid-free bovine serum albumin (Roche, Mannheim, Ger-
many) with a molar ratio of 1:1. Equal amounts of bovine serum
albumin were added to control cells.
2.2. Subjects
The study protocol was approved by the local ethics committee,
and the investigation conforms with the principles outlined in the
Declaration of Helsinki (1997). Each proband gave written in-
formed consent.
Monocytes were isolated from the blood of male T2D patients,
male controls with a BMI > 25 kg/m2 (overweight control group,
OW), and male controls with a BMI 6 25 kg/m2 (normal-weight
controls, NW). Details of the study groups are given in Table 1 for
donors whose monocytes were used in immunoblot experiments
and in Table 2 for donors where cells were isolated to measure
soluble galectin-3. This cohort includes the probands listed in Table
1.
2.3. Real-time polymerase chain reaction (PCR)
Real-time PCR was performed as described elsewhere [20,25].
The speciﬁcity of the PCRs was conﬁrmed by sequencing of the
PCR fragments (Geneart, Regensburg, Germany). Galectin-3 wasTable 1
Anthropometrical and biochemical characteristics of the male study group used for the is
T2D OW
Probands (n) 7 10
BMI (kg/m2) 28.2 (27.0–56.2) 29.7
WHR 1.00 (1.00–1.08) 1.01
Apm (lg/ml) 1.2 (0.7–2.5) 3.6 (
Cellular galectin-3 (arbitrary units) 13.0 (6.3–24.0) 6.3 (
Body mass index (BMI), normal-weight controls (NW), overweight controls (OW), type
a Signiﬁcance of T2D versus OW.
b Signiﬁcance of OW versus NW.
c Signiﬁcance of T2D versus NW.ampliﬁed with galectin-3 uni (50-tgtttgcaatacaaagctgga-30) and
galectin-3 rev (50-tggtgaggtctatgtcaccaga-30).
2.4. Isolation and culture of primary blood monocytes
Peripheral blood leukocytes were isolated from 16 ml of whole
blood by Vacutainer CPT, and monocytes were further puriﬁed by
magnetic separation with CD14 beads (Miltenyi Biotec, Bergisch
Gladbach, Germany) [33]. Serum was coagulated with Thromborel
S (Roche) and CaCl2 and was dialyzed three-times against phos-
phate buffered saline (PBS) for 2 h each. 3  106 Monocytes were
cultivated in 1 ml RPMI supplemented with 10% autologous serum
for 24 h. Subsequently, the medium was replaced. Monocytes were
either cultivated in RPMI supplemented with 10% autologous ser-
um or in the identical medium supplemented with recombinant
adiponectin and 10 lg/ml were used until indicated otherwise.
Supernatants were collected 24 h later except as noted otherwise
and used for ELISA.
2.5. SDS–PAGE and immunoblotting
3  106 Monocytes were washed with PBS and solubilized in
50 ll RIPA buffer. Protein (15 lg) was separated by SDS–PAGE and
transferred to polyvinylidene ﬂuoride (PVDF) membranes (Bio-
Rad, München, Germany). Incubations with antibodies were per-
formed in1.5%bovine serumalbumin (BSA) in PBS, 0.1%Tweenover-olation of blood monocytes (all males).
NW P-value
10
(26.7–33.3) 23.9 (20.1–24.9) <0.001b,c
(0.94–1.09) 0.96 (0.84–1.05) 0.03c
1.2–9.4) 4.0 (1.4–6.7) 0.003a, <0.001c
4.3–9.6) 4.2 (1.4–7.9) 0.007a, 0.029b, <0.001c
2 diabetes (T2D), waist to hip ratio (WHR).
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enhanced chemiluminescence (ECL) Western blot detection system
(Amersham Pharmacia, Deisenhofen, Germany). Quantiﬁcation of
the immunoblots was performed using OptiQuant software.
2.6. Enzyme-linked immunosorbent assay (ELISA)
Adiponectin ELISA was performed as described [25]. ELISAs to
measure galectin-3 in the supernatants were performed as recom-
mended by the distributor. Supernatants were diluted 1:4-fold.
Monocytes were cultivated in 10% autologous serum and galec-
tin-3 was also measured in serum of 10 normal-weight males. Con-
centrations were 3.4 (2.9–3.6) ng/ml and, therefore, less than 5% of
galectin-3 in the supernatants of the monocytes with 17.6 (7.5–
43.7, Fig. 1B) ng/ml accord to serum galectin-3.
2.7. Statistics
Data are presented as themedian values and the range of the val-
ues (SPSS 15.0 for Windows). Statistical differences were analyzed
by two-tailed Mann–Whitney U test or Students t-test for paired
samples, and a value of P < 0.05 was regarded as statistically signif-
icant. The Pearson’s correlation was calculated using the SPSS 15.0
software.
3. Results
3.1. Adiponectin reduces monocytic galectin-3
Monocytes were isolated from the blood of ﬁve different nor-
mal-weight donors and subsequently cultivated with or withoutFig. 1. Adiponectin downregulates galectin-3. (A) Galectin-3 and GAPDH in monocytes o
(B) Soluble (sol.) galectin-3 was determined by ELISA in the supernatants of monocytes of
monocytes cultivated with 10 lg/ml adiponectin or without adiponectin for 18, 24 or 30
ml adiponectin for 24 h. (E) Soluble (sol.) galectin-3 was determined by ELISA in the sup
24 h.10 lg/ml adiponectin for 24 h. Immunoblot analysis was per-
formed, and galectin-3 protein was found reduced in the mono-
cytes incubated with adiponectin. A representative result of two
experiments is shown (Fig. 1A). Quantiﬁcation of the immunoblots
of the ﬁve independent experiments revealed that galectin-3 was
8.6 (7.2–9.1) in control cells and 6.0 (4.2–6.1) in adiponectin-incu-
bated monocytes (P = 0.001). Galectin-3 mRNA expression was
determined using monocytes of eight different donors, and mRNA
levels were nearly 2-fold reduced in adiponectin-incubated cells
(P = 0.004, data not shown). Galectin-3 is also released to the
supernatants and was reduced by about 15% in adiponectin-trea-
ted monocytes of the 13 donors described above (Fig. 1B).
To determine the time-dependent reduction of galectin-3 in
monocytes, cells of three different donors were treated with or
without 10 lg/ml adiponectin for 18 h, 24 h and 30 h, whereas
galectin-3 in control treated cells was increased during cultiva-
tion, a signiﬁcant downregulation of galectin-3 was observed in
the adiponectin-treated cells after 24 h. A similar decrease was
found in monocytes incubated with adiponectin for 30 h
(Fig. 1C).
The effects of increasing amounts of adiponectin on galectin-3
were investigated using monocytes of three different donors that
were incubated for 24 h. A similar reduction of galectin-3 was de-
tected in monocytes treated with 10.0, 12.5 and 15.0 lg/ml adipo-
nectin. 7.5 lg/ml Adiponectin slightly reduced galectin-3 whereas
5 lg/ml did not lower galectin-3 (Fig. 1D and data not shown).
Similarly, soluble galectin-3 was signiﬁcantly reduced by 10 lg/
ml adiponectin. 7.5 lg/ml of the Protein tended to lower galec-
tin-3 whereas 5.0 lg/ml had no effect. A further reduction was ob-
served in monocytes incubated with 15.0 lg/ml recombinant
adiponectin (Fig. 1E).f two blood donors cultivated with or without 10 lg/ml adiponectin (Apm) for 24 h.
13 individuals that were cultivated as described in (A). (C) Galectin-3 and GAPDH in
h. (D) Galectin-3 and GAPDH in monocytes cultivated with 7.5, 10.0, 12.5 and 15 lg/
ernatants of monocytes cultivated with 5.0, 7.5, 10.0, and 15 lg/ml adiponectin for
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Adiponectin, the antidiabetic drug metformin and AICAR acti-
vate the AMPK, and the inﬂuence of these drugs on galectin-3
was analysed. Metformin at 1 mM reduced galectin-3 whereas
lower concentrations (0.5 mM, 0.1 mM) had no effect (Fig. 2A
and data not shown). Further, reduced galectin-3 was observed
in monocytes of two different donors incubated with 0.5 mM AI-
CAR for 24 h (Fig. 2B). Compound C inhibits AMPK activation and
1 and 2.5 lM of this inhibitor abolished adiponectin-mediated
repression of galectin-3. However, galectin-3 was reduced in
monocytes incubated with the inhibitor alone compared to con-
trol-cultivated cells (Fig. 2C), and additional experiments with a
more speciﬁc AMPK antagonist have to conﬁrm the involvement
of AMPK in adiponectin-mediated suppression of galectin-3.
3.3. Endogenous galectin-3 is not affected by free fatty acids and
cellular cholesterol concentrations
Systemic free fatty acids are elevated in obesity, and it was ana-
lysed whether palmitic acid or oleic acid at a concentration of 100,
200 or 300 lM affect cellular galectin-3 but galectin-3 was not al-
tered (Fig. 2D). Accumulation of cholesterol is characteristic for
foam cell formation, and the effects of lovastatin (5 lM, 24 h) that
lowers cellular cholesterol levels and cyclodextrin (1 mg/ml, 12 h)
that selectively removes plasma membrane cholesterol were
investigated. The experiments revealed that cellular galectin-3 is
not affected by these treatments (Fig. 2E).
3.4. Cellular galectin-3 is elevated in T2D monocytes and its soluble
form is reduced
Adiponectin is reduced in obesity and downregulates cellular
and soluble galectin-3 in vitro. To ﬁnd out whether this effect is
also relevant in vivo monocytes were isolated from the blood of
normal-weight controls (NW, 10 donors), overweight donors
(OW, 10 donors) and T2D patients (7 donors) (Table 1). Immuno-Fig. 2. Metformin, AICAR and compound C reduce galectin-3. (A) Galectin-3 and GAPD
Galectin-3 in monocytes incubated with 0.5 mM 5-aminoimidazole-4-carboxamide-1
adiponectin, 1 or 2.5 lM compound C (Comp C) alone or in combination with adiponecti
acid (PA) or oleic acid (OA) for 24 h. (E) Galectin-3 in monocytes incubated with 5 lM lblots were performed with these cell lysates, and representative
results are shown in Fig. 3A and B. Quantiﬁcation of the immuno-
blots revealed that galectin-3 was highest in T2D cells, signiﬁcantly
reduced in OW cells and lowest in NW cells (Fig. 3C, Table 1). The
levels of soluble galectin-3 in the supernatants of the monocytes,
however, were signiﬁcantly lower in T2D (23 donors) compared
to OW (20 donors) and NW (20 donors) with similar concentra-
tions (Fig. 3D, Table 2).
Cellular galectin-3 positively correlated with the BMI of the
blood donors (r = 0.81, P < 0.001, Fig. 3E) and negatively with galec-
tin-3 in the supernatants (r = 0.56, P = 0.004, Fig. 3F). However,
soluble galectin-3 only showed a modest negative correlation with
the BMI (r = 0.26, P = 0.037, Fig. 3G). Neither cellular nor soluble
galectin-3 correlated to systemic adiponectin levels, LDL, HDL or
fasting glucose of the respective donors (data not shown).
3.5. Impaired adiponectin-mediated suppression of galectin-3 in T2D
monocytes
The effect of adiponectin on galectin-3 levels was compared in
the 3 study cohorts. Immunoblot analysis revealed that the sup-
pression of galectin-3 was impaired in T2D cells of four donors
whereas a slight reduction was observed in monocytes of two
T2D patients (a representative result is shown in Fig. 3H). Since cel-
lular and soluble galectin-3 are lowered by adiponectin, galectin-3
was measured in the supernatants of the cells of all donors listed in
Table 2. Whereas adiponectin signiﬁcantly reduced galectin-3 in
the supernatants of OW and NW cells, this effect was not signiﬁ-
cant in T2D monocytes (Fig. 3I).
4. Discussion
In the current study it is demonstrated that adiponectin down-
regulates galectin-3 mRNA expression, endogenous and soluble
galectin-3. Cellular galectin-3 is reduced by about 30% and soluble
galectin-3 by about 10 to 20% when monocytes are incubated with
10 lg/ml adiponectin for 24 h. Although reduced soluble galectin-3H in monocytes incubated with 0.5 mM or 1 mM metformin (Metf) for 24 h. (B)
-4-ribofuranoside (AICAR) for 24 h. (C) Galectin-3 in monocytes incubated with
n for 24 h. (D) Galectin-3 in monocytes incubated with 100, 200 or 300 lM palmitic
ovastatin for 24 h or 1 mg/ml cyclodextrin for 12 h.
Fig. 3. Galectin-3 in monocytes of normal-weight and overweight controls and type 2 diabetic (T2D) patients. (A) Galectin-3 in monocytes isolated from the blood of
overweight (OW_1, OW_2) and normal-weight controls (NW_1, NW_2). (B) Galectin-3 in monocytes isolated from the blood of type 2 diabetic patients (T2D_1, T2D_2) and
overweight controls (OW_3, OW_4). (C) Quantiﬁcation of the immunoblots with representative results shown in (A) and (B) (arbitrary units, a.u.). (D) Galectin-3 in the
supernatants of T2D, OW and NWmonocytes. (E) Correlation of cellular galectin-3 with the BMI of the blood donors (arbitrary units, a.u.). (F) Correlation of cellular galectin-3
with soluble galectin-3 (arbitrary units, a.u.). (G) Correlation of soluble galectin-3 with the BMI of the blood donors. (H) Galectin-3 and GAPDH in monocytes of a NW blood
donor and of a T2D patient cultivated with or without 10 lg/ml adiponectin (Apm) for 24 h. (I) Soluble galectin-3 in the supernatants of adiponectin-incubated monocytes of
T2D patients, OW and NW probands in% of cells cultivated without adiponectin set to 100% (control).
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galectin-3 show an inverse correlation indicating that low cellular
protein is more likely associated with higher soluble concentra-
tions. Therefore, besides lowering cellular galectin-3 synthesis
adiponectin may also reduce galectin-3 release or induce its
degradation.
Adiponectin, metformin and AICAR activate AMPK [29–31], and
all reduce cellular galectin-3 indicating that AMPK may be in-
volved. Compound C is a AMPK inhibitor [34] and blocks adiponec-
tin-mediated suppression of galectin-3. However, this inhibitor
even lowers galectin-3 when added to control-cultivated mono-
cytes in commonly used concentrations indicating that compound
C may affect cell physiology also independent of AMPK inhibition
[34]. Therefore, it is likely that AMPK is involved in adiponectin-
mediated suppression of galectin-3 but additional experiments
using more speciﬁc AMPK antagonists have to be performed to
conﬁrm this suggestion.Adiponectin protects from atherosclerotic diseases and insulin
resistance, but circulating levels are reduced in these patients
[35,36]. In addition, adiponectin receptor proteins are suppressed
in monocytes of T2D patients indicating adiponectin resistance
[25]. Elevated cellular galectin-3 in T2D cells and monocytes of
overweight donors may at least in part be explained by an reduced
bioactivity of adiponectin. Furthermore, soluble galectin-3 was sig-
niﬁcantly reduced in the supernatants of T2D cells, and the nega-
tive correlation of cellular and soluble galectin-3 indicates that
galectin-3 release is also impaired in T2D monocytes, and this
may further contribute to elevated cellular levels. Cellular galec-
tin-3 positively correlates with the BMI of the respective blood do-
nors, and therefore, factors that are altered in obesity and/or type 2
diabetes may inﬂuence monocytic galectin-3 levels. However, sol-
uble galectin-3 only modestly correlates with the BMI indicating a
complex regulation of galectin-3 release. Inﬂammatory stimuli as
lipopolysaccharide, cytokines, chemokines and systemic free fatty
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by elevated levels of atherogenic LDL particles, and reduced HDL
is one characteristic of the metabolic syndrome and contributes
to atherosclerotic diseases [39]. LPS reduces cellular galectin-3
[5] whereas free fatty acids have no effect on endogenous galec-
tin-3 levels, and therefore, may not explain high cellular galectin-
3 in T2D monocytes. Atherogenic lipoproteins like oxidized LDL or
acetylated LDL increase cellular galectin-3 [6] and this may con-
tribute to higher levels in monocytes of T2D patients and obese
probands. Nevertheless, removal of cellular or plasma membrane
cholesterol in monocytes that were not loaded with lipids does
not alter galectin-3 indicating that galectin-3 levels do not simply
reﬂect cellular cholesterol content. Furthermore, galectin-3 is sig-
niﬁcantly higher in T2D cells compared to monocytes of the obese
controls, and factors that are speciﬁcally altered in T2D, like hyper-
glycemia, but are not related to simple obesity may also be
involved.
Neither cellular nor soluble galectin-3 in the supernatants of the
monocytes correlated with systemic adiponectin. In the current
study total adiponectin concentrations were measured in serum.
Isoform speciﬁc effects of adiponectin have been described
[20,28] and high-molecular complexes are currently suggested to
exert the insulin sensitizing effects of adiponectin [40,41]. Full-
length adiponectin which forms hexamers and high-molecular
weight complexes [20] has been used for the experiments de-
scribed herein and this might in part explain the failure to detect
an association of cellular galectin-3 with total adiponectin levels.
Whereas soluble galectin-3 is a proapoptotic protein endoge-
nous galectin-3 is protective and a dysbalance in galectin-3 distri-
bution may prolong the life time of T2D monocytes [5]. This may
explain elevated numbers of circulating monocytes in type 2 dia-
betic patients already described in a recent study [42] and inﬂam-
mation [43]. Adiponectin induces apoptotic cell death in myeloid
cell lines and myelomonocytic progenitor cells [21] but whether
adiponectin alters galectin-3 in these cells has not been analysed
yet. Adiponectin-mediated reduction of anti-apoptotic cellular
and proapoptotic soluble galectin-3 in monocytes, however, is
not associated with cell death [20].
Soluble galectin-3 recognizes galactoside-containing glycocon-
jugates on pathogens like Escherichia coli or Klebsiella pneumoniae
and stimulates host defense activity of phagocytes [5]. Low soluble
galectin-3 in T2D cells may be associated with an impaired im-
mune response in infections [44]. In addition, galectin-3 deﬁciency
is associated with a lower degree of inﬂammation in metabolic dis-
eases like atherosclerosis although this ﬁndings were obtained in
galectin-3 deﬁcient mice where the individual effects of cellular
and soluble galectin-3 can not be distinguished [13].
In summary, the current data indicate that adiponectin reduces
monocyte galectin-3 whose endogenous level is elevated whereas
its soluble form is reduced in T2D monocytes, and this may con-
tribute to inﬂammation and the impaired immune response in dia-
betic patients.
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